Skip to content

Feasibility of a Whole-Food, Plant-Based Diet for Patients With Low-Risk Chronic Lymphocytic Leukemia (CLL)

Feasibility of a Whole-Food, Plant-Based Dietary Intervention for Patients With Low-Risk Chronic Lymphocytic Leukemia

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06377501
Enrollment
19
Registered
2024-04-22
Start date
2023-03-07
Completion date
2024-07-01
Last updated
2025-09-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Lymphocytic Leukemia Stage A(0)

Keywords

whole-food plant-based diet, CLL

Brief summary

This study will evaluate the feasibility of an 8-week vegan whole-food, plant-based dietary intervention in subjects with low risk CLL who are undergoing observation. Over the course of 8 weeks, participants will attend weekly group cooking classes via Zoom lead by a RD. Participants will also attend weekly individual meetings with a health coaches to assist with adherence to the dietary intervention.

Interventions

Subjects will be instructed to adopt a whole-food, plant-based diet for 8 weeks. They will attend weekly group cooking classes led by a RD and receive weekly health coaching sessions.

Sponsors

University of California, San Diego
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients who have a diagnosis of low-risk CLL according to the modified Rai staging criteria for a minimum of 12 months and are currently undergoing observation. * Access to a computer or tablet and Zoom.

Exclusion criteria

* Have active disease and are currently receiving pharmacologic treatment for CLL * Have previously received treatment for CLL * Are currently following a vegan or vegetarian diet * A previous or current diagnosis of disordered eating including anorexia, bulimia, binge eating disorder or avoidant/restrictive food intake disorder. * A diagnosis of Type 1 diabetes * A diagnosis of Insulin dependent type 2 diabetes * Currently pregnant or planning to become pregnant

Design outcomes

Primary

MeasureTime frameDescription
Adherence to the Dietary InterventionUp to 24 weeksAdherence to the dietary intervention will be calculated using a dietary index developed specifically for this diet. Dietary adherence scores will be calculated using a pre- and post-intervention food frequency questionnaire, as well as 3-day food diaries obtained throughout the intervention.
Satisfaction with the Dietary Intervention8 weeksSubject satisfaction will be assessed post-intervention using an acceptability, appropriateness and feasibility questionnaire. The questionnaire does not use a scoring system, rather statements will be provided and participants will provide an answer ranging from completely disagree to completely agree.
Cooking Class Adherence8 weeksCooking class attendance will also be used as a measure of adherence.
RecruitmentThrough study completion, an average of 1 yearRecruitment rate will be assessed by examining the number of potentially eligible participants, number contacted, consent rates, number completing the intervention.
Retention8 weeksRetention will be calculated using the number of participants who enroll in the study and the number of participants who complete the 8 week intervention.

Secondary

MeasureTime frameDescription
Biomarkers of cardiometabolic health (hemoglobin A1c)Change from baseline at 4 weeks and 8 weeks.Will be measured using standard methods.
Biomarkers of cardiometabolic health (cholesterol and triglycerides)Change from baseline at 4 weeks and 8 weeks.Will be measured using standard methods.
Concentration of vitamin B12Change from baseline at 4 and 8 weeks.Will be measured using standard methods.
White blood cell countChange from baseline at 4 weeks and 8 weeks.Will be measured using standard methods.
Concentration of ironChange from baseline at 4 and 8 weeks.Will be measured using standard methods.
Concentration of ferritinChange from baseline at 4 and 8 weeks.Will be measured using standard methods.
Blood pressureChange from baseline at 4 weeks and 8 weeks.Will be measured using standard methods, both systolic and diastolic blood pressure will be assessed.
Concentration of vitamin B9Change from baseline at 4 and 8 weeks.Will be measured using standard methods.
Absolute lymphocyte countChange from baseline at 4 weeks and 8 weeks.Will be measured using standard methods.
Anthropometric Measures (height, weight, body mass index)Change from baseline at 4 weeks and 8 weeks.Will be measured using standard methods. Weight and height will be combined to report BMI in kg/m\^2.
Anthropometric Measures (waist circumference)Change from baseline at 4 weeks and 8 weeks.Will be measured using standard methods. Weight and height will be combined to report BMI in kg/m\^2.
Biomarkers of cardiometabolic health (complete metabolic panel)Change from baseline at 4 weeks and 8 weeks.Will be measured using standard methods.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026